STOCK TITAN

Corcept Therapeutics: Wilson trust sells 10,000 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Corcept Therapeutics (CORT) director James N. Wilson reported that the James N. Wilson and Pamela D. Wilson Trust sold 10,000 shares of common stock on November 13, 2026. The four reported weighted-average sale prices were $71.8011, $72.8666, $73.4192 and $74.2800 per share. The sales were made under a 10b5-1 plan adopted March 12, 2026. Wilson has voting power over the trust’s shares and disclaims beneficial ownership except to the extent of his pecuniary interest. Separately reported indirect holdings included 200,000 shares in James N. Wilson 2025 Grantor Retained Annuity Trust and 200,000 shares in Pamela D. Wilson 2025 Grantor Retained Annuity Trust.

Insider WILSON JAMES N
Role Director
Sold 10,000 shs ($727K)
Type Security Shares Price Value
Sale Common Stock F1, F2, F5 2,191 $71.8011 $157K
Sale Common Stock F1, F3, F5 7,221 $72.8666 $526K
Sale Common Stock F1, F4, F5 563 $73.4192 $41K
Sale Common Stock F1, F5 25 $74.28 $2K
Holding Common Stock -- -- --
Holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 1,044,543 shares (Indirect, James N. Wilson and Pamela D. Wilson Trust); Common Stock — 200,000 shares (Indirect, James N. Wilson 2025 Grantor Retained Annuity Trust); Common Stock — 200,000 shares (Indirect, Pamela D. Wilson 2025 Grantor Retained Annuity Trust)
Footnotes (5)
  1. F1. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction.
  2. F2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $71.18 to $72.17 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  3. F3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $72.18 to $73.155 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  4. F4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.22 to $73.88 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
  5. F5. Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
Shares sold 10,000 shares By the James N. Wilson and Pamela D. Wilson Trust on November 13, 2026
Sale tranche 2,191 shares at $71.8011 per share Weighted-average sale price on November 13, 2026
Sale tranche 7,221 shares at $72.8666 per share Weighted-average sale price on November 13, 2026
Sale tranche 563 shares at $73.4192 per share Weighted-average sale price on November 13, 2026
Sale tranche 25 shares at $74.2800 per share Reported sale price on November 13, 2026
Indirect trust holding 200,000 shares James N. Wilson 2025 Grantor Retained Annuity Trust; reported November 13, 2026
Indirect trust holding 200,000 shares Pamela D. Wilson 2025 Grantor Retained Annuity Trust; reported November 13, 2026
10b5-1 plan financial
"made pursuant to a 10b5-1 plan adopted March 12, 2026"
A 10b5-1 plan is a pre-arranged strategy that allows company insiders to buy or sell their shares at predetermined times and prices, even while they are aware of confidential information. It acts like a scheduled appointment for trading, helping ensure transactions happen transparently and legally, which can reassure investors that trades are not based on insider knowledge.
weighted average sale price financial
"Represents the weighted average sale price for the entire number of shares sold"
pecuniary interest financial
"except to the extent of his pecuniary interest therein"
Grantor Retained Annuity Trust financial
"James N. Wilson 2025 Grantor Retained Annuity Trust"
A grantor retained annuity trust (GRAT) is an estate-planning tool where the person who creates the trust transfers assets into it but receives fixed cash payments (an annuity) from the trust for a set number of years; whatever remains after that term passes to designated beneficiaries. It matters to investors because it can shift future appreciation of assets out of the creator’s taxable estate—like putting an asset into a timed vending machine that pays you fixed amounts while any extra value that grows inside the machine goes to heirs with reduced gift or estate tax consequences.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CORT shares did the Wilson trust sell, and at what prices?

The James N. Wilson and Pamela D. Wilson Trust sold 2,191 shares at a weighted-average $71.8011 per share, 7,221 at $72.8666, 563 at $73.4192 and 25 at $74.2800 on November 13, 2026. The reported actual sale-price ranges for the first three groups were $71.18–$72.17, $72.18–$73.155 and $73.22–$73.88, respectively.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
WILSON JAMES N

(Last)(First)(Middle)
C/O CORCEPT THERAPEUTICS INCORPORATED
101 REDWOOD SHORES PARKWAY

(Street)
REDWOOD CITY CALIFORNIA 94065

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/13/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/13/2026S(1)2,191D$71.8011(2)1,052,352IJames N. Wilson and Pamela D. Wilson Trust(5)
Common Stock11/13/2026S(1)7,221D$72.8666(3)1,045,131IJames N. Wilson and Pamela D. Wilson Trust(5)
Common Stock11/13/2026S(1)563D$73.4192(4)1,044,568IJames N. Wilson and Pamela D. Wilson Trust(5)
Common Stock11/13/2026S(1)25D$74.281,044,543IJames N. Wilson and Pamela D. Wilson Trust(5)
Common Stock200,000IJames N. Wilson 2025 Grantor Retained Annuity Trust
Common Stock200,000IPamela D. Wilson 2025 Grantor Retained Annuity Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction.
2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $71.18 to $72.17 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $72.18 to $73.155 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.22 to $73.88 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
5. Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
Remarks:
The power of attorney under which this form was signed is on file with the Commission.
/s/ Joseph Douglas Lyon, as attorney-in-fact for James N. Wilson11/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading